Who has been buying HLB Life Science stock?

3 distinct insiders have filed 6 disclosed insider purchases in HLB Life Science (067630), most recently on 2026-06-30. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does HLB Life Science have?

HLB Life Science has 6 buy-side and 0 sell-side disclosures on record, spanning 2023-03-31 to 2026-06-30.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

HLB Life Science 067630

Company

HLB생명과학HLB Life Science

Insiders

Buys

Total Value

—

Avg Return

—

Last Filing

2026-06-30

HLB Life Science (067630) has 6 disclosed insider purchases and 0 disclosed disposals on record, filed by 3 distinct insiders. The earliest filing StockDrifts holds for HLB Life Science is dated 2023-03-31; the most recent is 2026-06-30.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-06-30	BUY	Market Buy	유춘성 Yu Chun-seong	vice president	1.5K	-	-	-
2026-06-30	BUY	Market Buy	백윤기 Baek Yoongi	CEO	3.3K	-	-	-
2026-06-29	BUY	Market Buy	백윤기 Baek Yoongi	CEO	88	-	-	-
2026-06-26	BUY	신규보고	정성욱 Seongwook Jeong	moving	1.8K	-	-	-
2026-06-26	BUY	Market Buy	백윤기 Baek Yoongi	CEO	3.0K	-	-	-
2026-06-26	BUY	Market Buy	이길현 Lee Gil-hyeon	moving	1.0K	-	-	-
2026-06-25	BUY	Market Buy	유춘성 Yu Chun-seong	vice president	2.0K	-	-	-
2026-06-25	BUY	신규보고	이길현 Lee Gil-hyeon	moving	1.0K	-	-	-
2026-06-25	BUY	신규보고	백윤기 Baek Yoongi	CEO	3.0K	-	-	-
2026-06-24	BUY	신규보고	유춘성 Yu Chun-seong	vice president	1.0K	-	-	-
2024-12-16	SELL	풋옵션권리행사에따른주식처분	HLB	-	-2.3M	₩9,970	+60.5%	₩22.6B ($15.7M)
2024-12-10	BUY	전환사채의권리행사	조용호 Cho Yong-ho	president	3.2M	₩9,940	-60.4%	₩31.8B ($22.1M)
2024-12-10	SELL	전환권등소멸	조용호 Cho Yong-ho	president	-3.2M	₩9,940	+60.4%	₩31.8B ($22.1M)
2024-11-07	BUY	행사가액조정	조용호 Cho Yong-ho	president	122.4K	₩8,500	-53.7%	₩1.0B ($722K)
2024-06-25	SELL	기타	HLB	-	-1.0M	₩9,270	+57.5%	₩9.3B ($6.5M)
2024-06-25	BUY	행사가액조정	조용호 Cho Yong-ho	president	76.8K	₩9,270	-57.5%	₩712M ($495K)
2024-06-25	BUY	유상신주취득	HLB	-	1.0M	₩9,270	-57.5%	₩9.3B ($6.5M)
2024-06-25	BUY	행사가액조정	HLB	-	56.3K	₩9,270	-57.5%	₩522M ($362K)
2024-06-17	BUY	행사가액조정	HLB	-	1.5K	₩8,860	-55.6%	₩13M ($9K)
2024-05-28	SELL	장외매도	HLB	-	-1.0M	₩10,020	+60.7%	₩10.1B ($7.0M)
2024-05-22	BUY	기타	HLB	-	2.0M	₩8,760	-55.1%	₩17.6B ($12.3M)
2023-03-31	BUY	기타	HLB	-	1	₩10,660	-63.1%	₩11K ($7)

Frequently asked questions

Who has been buying HLB Life Science stock?: 3 distinct insiders have filed 6 disclosed insider purchases in HLB Life Science (067630), most recently on 2026-06-30. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does HLB Life Science have?: HLB Life Science has 6 buy-side and 0 sell-side disclosures on record, spanning 2023-03-31 to 2026-06-30.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.